JBC PeproTech; Our Business is Cytokines!

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M606441200 on August 25, 2006

J. Biol. Chem., Vol. 281, Issue 42, 31486-31494, October 20, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
281/42/31486    most recent
M606441200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Norstrøm, E. A.
Right arrow Articles by Dahlbäck, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Norstrøm, E. A.
Right arrow Articles by Dahlbäck, B.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Effects of Factor Xa and Protein S on the Individual Activated Protein C-mediated Cleavages of Coagulation Factor Va*

Eva A. Norstrøm, Sinh Tran, Mårten Steen, and Björn Dahlbäck1

From the Department of Laboratory Medicine, Clinical Chemistry, Lund University, the Wallenberg Laboratory, University Hospital, Malmö, SE-205 02 Malmö, Sweden

Activated protein C inhibits the procoagulant function of activated factor V (FVa) through proteolytic cleavages at Arg-306, Arg-506, and Arg-679. The cleavage at Arg-506 is kinetically favored but protected by factor Xa (FXa). Protein S has been suggested to annihilate the inhibitory effect of FXa, a proposal that has been challenged. To elucidate the effects of FXa and protein S on the individual cleavage sites of FVa, we used recombinant FVa:Q306/Q679 and FVa:Q506/Q679 variants, which can only be cleaved at Arg-506 and Arg-306, respectively. In the presence of active site blocked FXa (FXa-1.5-dansyl-Glu-Gly-Arg), the FVa inactivation was followed over time, and apparent second order rate constants were calculated. Consistent with results on record, we observed that FXa-1.5-dansyl-Glu-Gly-Arg decreased the Arg-506 cleavage by 20-fold, with a half-maximum inhibition of ~2 nM. Interestingly and in contrast to the inhibitory effect of FXa on the 506 cleavage, FXa stimulated the Arg-306 cleavage. Protein S counteracted the inhibition by FXa of the Arg-506 cleavage, whereas protein S and FXa yielded additive stimulatory effect of the cleavage at Arg-306. This suggests that FXa and protein S interact with distinct sites on FVa, which is consistent with the observed lack of inhibitory effect on FXa binding to FVa by protein S. We propose that the apparent annihilation of the FXa protection of the Arg-506 cleavage by protein S is due to an enhanced rate of Arg-506 cleavage of FVa not bound to FXa, resulting in depletion of free FVa and dissociation of FXa-FVa complexes.


Received for publication, July 6, 2006 , and in revised form, August 25, 2006.

* This work was supported by grants from the Network for Cardiovascular Research funded by the Swedish Foundation for Strategic Research, by grants from the Swedish Council (#07143), a senior Investigator's Award from the Foundation for Strategic Research, the Söderberg, Österlund, and Påhlsson trusts, and by research funds from the University Hospital in Malmö. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom correspondence should be addressed. Tel.: 46-40-33-15 01; Fax: 46-40-33-70-44; E-mail: bjorn.dahlback{at}med.lu.se.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
M. Steen, S. Tran, L. Autin, B. O. Villoutreix, A.-L. Tholander, and B. Dahlback
Mapping of the Factor Xa Binding Site on Factor Va by Site-directed Mutagenesis
J. Biol. Chem., July 25, 2008; 283(30): 20805 - 20812.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. F. A. Maurissen, M. C. L. G. D. Thomassen, G. A. F. Nicolaes, B. Dahlback, G. Tans, J. Rosing, and T. M. Hackeng
Re-evaluation of the role of the protein S-C4b binding protein complex in activated protein C-catalyzed factor Va-inactivation
Blood, March 15, 2008; 111(6): 3034 - 3041.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Tran, E. Norstrom, and B. Dahlback
Effects of Prothrombin on the Individual Activated Protein C-mediated Cleavages of Coagulation Factor Va
J. Biol. Chem., March 14, 2008; 283(11): 6648 - 6655.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Yegneswaran, Y. Kojima, P. M. Nguyen, A. J. Gale, M. J. Heeb, and J. H. Griffin
Factor Va Residues 311 325 Represent an Activated Protein C Binding Region
J. Biol. Chem., September 28, 2007; 282(39): 28353 - 28361.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.